DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SAN DIEGO, March 06, 2018 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 38th Annual Cowen and Company Health Care Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET (9:00 a.m. PT) at the Marriot Copley Place in Boston.
A live audio webcast of the presentation will be available through the Events and Presentations page of the company's website (www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for otology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
[email protected]
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]
